华兰疫苗
(301207)
| 流通市值：88.35亿 | | | 总市值：88.41亿 |
| 流通股本：6.01亿 | | | 总股本：6.01亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 300,886,999.93 | 44,385,271.38 | 26,775,352.59 | 1,202,505,820.54 |
| 营业收入 | 300,886,999.93 | 44,385,271.38 | 26,775,352.59 | 1,202,505,820.54 |
| 二、营业总成本 | 410,740,704.74 | 113,374,875.3 | 48,488,924.09 | 1,021,513,204.01 |
| 营业成本 | 112,372,997.54 | 23,154,568.96 | 7,786,364.4 | 266,941,314.06 |
| 税金及附加 | 7,007,741.25 | 2,953,713.77 | 1,575,601.62 | 10,239,569.21 |
| 销售费用 | 167,882,215.1 | 25,189,256.82 | 11,699,486.26 | 544,474,956.02 |
| 管理费用 | 48,921,708.04 | 19,458,692.52 | 6,946,003.55 | 50,323,036.8 |
| 研发费用 | 76,033,376.43 | 43,784,142.15 | 20,775,324.78 | 151,302,562.02 |
| 财务费用 | -1,477,333.62 | -1,165,498.92 | -293,856.52 | -1,768,234.1 |
| 其中:利息费用 | - | - | - | 2,550,000.02 |
| 其中:利息收入 | 1,591,335.11 | 1,207,773 | 318,173.62 | 4,444,764.66 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 9,852,879.8 | 7,484,705.83 | 4,066,763.04 | 12,726,022.07 |
| 加:投资收益 | 46,560,854.05 | 29,904,184.79 | 14,719,086.04 | 76,806,684.63 |
| 资产处置收益 | - | - | - | -204,773.66 |
| 资产减值损失(新) | 13,105,911.89 | 12,739,217.1 | 200,043.72 | -58,207,765.52 |
| 信用减值损失(新) | 18,074,021.79 | 51,585,326.69 | 41,591,811.05 | -30,713,440.61 |
| 其他收益 | 4,123,562.46 | 2,693,261.02 | 1,634,717.36 | 8,376,400.04 |
| 四、营业利润 | -18,136,474.82 | 35,417,091.51 | 40,498,849.71 | 189,775,743.48 |
| 加:营业外收入 | 116,418.34 | 116,418.34 | 1,374.09 | 212,240 |
| 减:营业外支出 | 309,334.95 | 81,733.51 | 29,874.64 | 2,202,055.93 |
| 五、利润总额 | -18,329,391.43 | 35,451,776.34 | 40,470,349.16 | 187,785,927.55 |
| 减:所得税费用 | -13,878,291.13 | -991,386.81 | 3,104,636.41 | 4,866,236.71 |
| 六、净利润 | -4,451,100.3 | 36,443,163.15 | 37,365,712.75 | 182,919,690.84 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -4,451,100.3 | 36,443,163.15 | 37,365,712.75 | 182,919,690.84 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -4,451,100.3 | 36,443,163.15 | 37,365,712.75 | 182,919,690.84 |
| 扣除非经常损益后的净利润 | -37,101,896.45 | 14,573,538.41 | 26,147,410.97 | 131,684,243.98 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.01 | 0.06 | 0.06 | 0.31 |
| (二)稀释每股收益 | -0.01 | 0.06 | 0.06 | 0.31 |
| 九、综合收益总额 | -4,451,100.3 | 36,443,163.15 | 37,365,712.75 | 182,919,690.84 |
| 归属于母公司股东的综合收益总额 | -4,451,100.3 | 36,443,163.15 | 37,365,712.75 | 182,919,690.84 |
| 公告日期 | 2026-10-28 | 2026-08-29 | 2026-04-27 | 2026-03-28 |
| 审计意见(境内) | | | | 标准无保留意见 |